» Articles » PMID: 20068184

Genetic Analysis of Transforming Events That Convert Chronic Myeloproliferative Neoplasms to Leukemias

Overview
Journal Cancer Res
Specialty Oncology
Date 2010 Jan 14
PMID 20068184
Citations 138
Authors
Affiliations
Soon will be listed here.
Abstract

The oncogenetic events that transform chronic myeloproliferative neoplasms (MPN) to acute myeloid leukemias (AML) are not well characterized. We investigated the role of several genes implicated in leukemic transformation by mutational analysis of 63 patients with AML secondary to a preexisting MPN (sAML). Frequent mutations were identified in TET2 (26.3%), ASXL1 (19.3%), IDH1 (9.5%), and JAK2 (36.8%) mutations in sAML, and all possible mutational combinations of these genes were also observed. Analysis of 14 patients for which paired samples from MPN and sAML were available showed that TET2 mutations were frequently acquired at leukemic transformation [6 of 14 (43%)]. In contrast, ASXL1 mutations were almost always detected in both the MPN and AML clones from individual patients. One case was also observed where TET2 and ASXL1 mutations were found before the patient acquired a JAK2 mutation or developed clinical evidence of MPN. We conclude that mutations in TET2, ASXL1, and IDH1 are common in sAML derived from a preexisting MPN. Although TET2/ASXL1 mutations may precede acquisition of JAK2 mutations by the MPN clone, mutations in TET2, but not ASXL1, are commonly acquired at the time of leukemic transformation. Our findings argue that the mutational order of events in MPN and sAML varies in different patients, and that TET2 and ASXL1 mutations have distinct roles in MPN pathogenesis and leukemic transformation. Given the presence of sAML that have no preexisting JAK2/TET2/ASXL1/IDH1 mutations, our work indicates the existence of other mutations yet to be identified that are necessary for leukemic transformation.

Citing Articles

Prognostic significance of ASXL1 mutations in acute myeloid leukemia: A systematic review and meta-analysis.

Sheikhi M, Rostami M, Ferns G, Ayatollahi H, Siyadat P, Ayatollahi Y Caspian J Intern Med. 2024; 15(2):202-214.

PMID: 38807730 PMC: 11129077. DOI: 10.22088/cjim.15.2.202.


A Brief Overview of the Molecular Landscape of Myelodysplastic Neoplasms.

Abdulbaki R, Pullarkat S Curr Oncol. 2024; 31(5):2353-2363.

PMID: 38785456 PMC: 11119831. DOI: 10.3390/curroncol31050175.


Advances in Molecular Understanding of Polycythemia Vera, Essential Thrombocythemia, and Primary Myelofibrosis: Towards Precision Medicine.

Tashkandi H, Elbaz Younes I Cancers (Basel). 2024; 16(9).

PMID: 38730632 PMC: 11083661. DOI: 10.3390/cancers16091679.


Management of isocitrate dehydrogenase 1/2 mutated acute myeloid leukemia.

Fruchtman H, Avigan Z, Waksal J, Brennan N, Mascarenhas J Leukemia. 2024; 38(5):927-935.

PMID: 38600315 PMC: 11073971. DOI: 10.1038/s41375-024-02246-2.


Altered erythropoiesis via JAK2 and ASXL1 mutations in myeloproliferative neoplasms.

Collins T, Laranjeira A, Kong T, Fulbright M, Fisher D, Sturgeon C Exp Hematol. 2024; 132:104178.

PMID: 38340948 PMC: 10978257. DOI: 10.1016/j.exphem.2024.104178.


References
1.
Abdel-Wahab O, Mullally A, Hedvat C, Garcia-Manero G, Patel J, Wadleigh M . Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood. 2009; 114(1):144-7. PMC: 2710942. DOI: 10.1182/blood-2009-03-210039. View

2.
Baxter E, Scott L, Campbell P, East C, Fourouclas N, Swanton S . Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005; 365(9464):1054-61. DOI: 10.1016/S0140-6736(05)71142-9. View

3.
James C, Ugo V, Le Couedic J, Staerk J, Delhommeau F, Lacout C . A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005; 434(7037):1144-8. DOI: 10.1038/nature03546. View

4.
Levine R, Belisle C, Wadleigh M, Zahrieh D, Lee S, Chagnon P . X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal.... Blood. 2006; 107(10):4139-41. PMC: 1895292. DOI: 10.1182/blood-2005-09-3900. View

5.
Theocharides A, Boissinot M, Girodon F, Garand R, Teo S, Lippert E . Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation. Blood. 2007; 110(1):375-9. DOI: 10.1182/blood-2006-12-062125. View